Skip to main content
. 2019 Jul 4;85(6):E1084–E1094. doi: 10.1093/neuros/nyz229

TABLE 5.

Symptomatic Outcomes Following Definitive GKRS for Vestibular Schwannomas

Post-treatment Symptoms % (Frequency): Transient symptoms % (Frequency): Persistent symptoms % (Frequency): Total symptoms (Persistent or transient)
Hearing loss (HL)
 New-onset HL 14.3% (3/21) 23.8% (5/21) 38.1% (8/21)
 Worsening of prior HL 3.9% (8/206) 50/206 (24.2%) 28.2% (58/206)
 Improvement of prior HL 1.0% (2/206)
FND
 New-onset FND 4.6% (10/217) 4.1% (9/217) 8.8% (19/217)
 Worsening of prior FND 0.0% (0/10) 0.0% (0/10) 0.0% (0/10)
 Improvement of prior FND 90% (9/10)
TND
 New-onset TND 2.5% (5/203) 4.4% (9/203) 6.9% (14/203)
 Worsening of prior TND (0.0%) 0/24 4.2% (1/24) 4.2% (1/24)
 Improvement of prior TND 79.2% (19/24)
Vertigo/dizziness/disequilibrium (V/D/D)
 New-onset V/D/D 10.8% (10/93) 16.1% (15/93) 26.9% (25/93)
 Worsening of prior V/D/D 6.0% (8/134) 6.0% (8/134) 11.9% (16/134)
 Improvement of prior V/D/D 62.7% (84/134)
Tinnitus
 New-onset tinnitus 1.9% (2/104) 5.8% (6/104) 7.7% (8/104)
 Worsening of prior tinnitus 0.8% (1/123) 5.7% (7/123) 6.5% (8/123)
 Improvement of prior tinnitus 83.7% (103/123)
Lateralized headache (HA)
 New-onset HA 1.0% (2/208) 2.4% (5/208) 7/208 (3.4%)
 Worsening of prior HA 0.0% (0/19) 0.0% (0/19) 0/19 (0.0%)
 Improvement of prior HA 18/19 (94.7%)